Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Conditions: Hepatocellular Carcinoma Non-resectable; Portal Vein Tumor Thrombus; Immune Checkpoint Inhibitors Interventions: Drug: Cadonilimab; Radiation: Stereotactic radiotherapy; Drug: Renvatinib Sponsor: First Affiliated Hospital of Guangxi Medical University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Hospitals | Liver Cancer | Research | Thrombosis